Fritz C. Eilber

University of California, Los Angeles — United States

Medicine · Health Sciences

48h-index7.5kcitations207works6.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(130), Cancer Research and Treatments(57), Nanoplatforms for cancer theranostics(42), Virus-based gene therapy research(37), Vascular Tumors and Angiosarcomas(25)

Publications206 total

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma
JAMA Network Open·2025Open Access
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients
Surgery·2025· 1 cited
PPARG governs adipogenic differentiation and cell state plasticity in well-differentiated and dedifferentiated liposarcoma
2025Open Access
Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper‐Progression of Disease
Journal of Surgical Oncology·2025Open Access
Acromioclavicular joint cyst presenting with findings concerning for a soft tissue tumor – a case report
Diagnostic Pathology·2024· 1 citedOpen Access
780 Targeting myeloid cells with BO-112 engages T cell immunity in combination with radiotherapy and checkpoint blockade in preclinical models and a phase 1 neoadjuvant clinical trial
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
The landscape of drug sensitivity and resistance in sarcoma
Cell stem cell·2024· 47 citedOpen Access
Targeting Asparagine Metabolism in Well-Differentiated/Dedifferentiated Liposarcoma
Cancers·2024· 3 citedOpen Access
Sarcoma in patients with Lynch syndrome and response to immunotherapy
Journal of Surgical Oncology·2023· 2 cited
Surgical Outcomes in Patients Treated with 5-Day Preoperative Radiotherapy for Soft Tissue Sarcoma
International Journal of Radiation Oncology*Biology*Physics·2023· 3 citedOpen Access
IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma
Cancers·2023· 4 citedOpen Access
Fibroblast Activation Protein Expression in Sarcomas
Sarcoma·2023· 32 citedOpen Access
The landscape of drug sensitivity and resistance in sarcoma
2023· 9 citedOpen Access
FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells
Clinical Nuclear Medicine·2023· 3 cited
Does “Low-Grade” Dedifferentiated Liposarcoma Exist? The Role of Mitotic Index in Separating Dedifferentiated Liposarcoma From Cellular Well-differentiated Liposarcoma
The American Journal of Surgical Pathology·2023· 20 cited
Abstract 203: A characterization of drug sensitivity and resistance in sarcoma
Cancer Research·2023· 1 cited
Supplementary Figure Legend and Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 1-4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figure 10 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
Supplementary Figures 1 - 4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Sarah Dry(28), Scott D. Nelson(24), Arun S. Singh(18), Robert M. Hoffman(16), Frederick R. Eilber(14), Tasuku Kiyuna(14), Kentaro Igarashi(14), Kei Kawaguchi(14), Takashi Murakami(13), Tara A. Russell(12), Bartosz Chmielowski(11), William D. Tap(9), Noah Federman(9), Johannes Czernin(7), Nicholas M. Bernthal(7), Ming Zhao(7), Yong Zhang(7), Kentaro Miyake(7), Matthias Benz(6), Martin Allen-Auerbach(6)